No allogeneic CTL responses are detected in vitro for the isolated mismatch in the HLA alleles C*03:03 and C*03:04. Hematopoietic stem cell transplantation (HSCT) with unrelated donors (UD) showed no association between the HLA-C allele mismatches (CAMM) with adverse outcomes; whereas antigen mismatches at this and other HLA loci have deleterious effects. It was hypothesized that the absence of effect of the CAMM resulted from the predominance of the mismatch C
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for many hematologic disorders. [1] [2] [3] Transplants in which patients and their related or unrelated donors (UD) match in all alleles of HLA-A, -B, -C and -DRB1 loci (8/8) have significantly superior outcomes compared with those having one or more mismatches (MMs) at these loci. In the United States, 31 to 75 percent of patients, depending on ethnic background, are able to find an 8/8 matched UD. 4, 5 For patients who lack 8/8 related or unrelated donors, alternative sources of allogeneic hematopoietic stem cells (HSC) are HLA-mismatched UD, cord blood units, or first-degree haplo-identical relatives. Although the use of UD with a single HLA mismatch (7/8) increases access to transplantation, transplants from HLA mismatched donors are associated with significantly higher risks for mortality and morbidity compared with those from 8/8 HLA matched donors. [6] [7] [8] [9] [10] Several algorithms that score the risk associated with HLA mismatches based on the sharing of serologic epitopes 11 and the location 12 or the physicochemical properties of the amino acid differences 13, 14 have been developed. None of these, however, have proven useful in independent validation studies. Other recent studies examining empirical outcome data identified specific HLA allele mismatch combinations or specific amino acid replacements that are associated with increased risk for severe acute graft versus host disease (aGVHD) 15 or decreased survival 16 compared to HLA matched transplants.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From It has been proposed that the prioritization of mismatched donors could be based on an evaluation of the magnitude of relative risks for adverse outcomes. 7 A Center for International Blood and Marrow Transplant Research (CIBMTR) study 7 of predominately bone marrow HSCTs performed using myeloablative conditioning suggested that a single HLA-A and -DRB1 mismatch appeared to be more deleterious than a single mismatch at HLA-B or -C; in contrast, a study evaluating the effect of HLA mismatches in HSCT with peripheral blood stem cells (PBSC) 8 found higher risks for mortality in the transplants presenting one antigen mismatch in HLA-C or one mismatch in HLA-B. Both studies reported that isolated allele level mismatches in HLA-C were not associated with detrimental effects in any outcome. 7, 8 It has been speculated that the effect of the a single mismatch at a given HLA locus is a reflection of the summation of various types of allele mismatch combinations. 15, 17 We reasoned that if different mismatches have distinct effects in the outcome of each individual transplant, the resulting locus effect in a cohort may depend on the prevalence of the mismatch, as well as on the biological adverse impact of each mismatch. A study evaluating the cytotoxic T-lymphocyte precursor (CTLp) frequencies directed against incompatibilities at the HLA-A, -B, and -C loci in donor-recipient pairs 18 showed a significant correlation between HLA class I incompatibilities and high CTLp frequencies, with the exception of pairs where the mismatch was between HLA-C*03:03/-C*03:04. In these mismatched pairs, no CTLp could be detected in spite of the fact that the alleles C*03:03/C*03:04 type distinctly by serology as HLA-Cw9 and Cw10, respectively.
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The HLA alleles C*03:03 and C*03:04 are frequently associated with the allele B*15:01 in populations with European ancestry. 20 In unrelated HSCT, many donor/recipient pairs that match at HLA-B*15:01 could still have an allele level mismatch at HLA-C*03. We hypothesized that the lack of impact of the HLA-C allele level mismatches as a whole in the previous CIBMTR studies 8,9 may have resulted from the high predominance and lack of immunogenicity of the HLA mismatch C*03:03/C*03:04 since this may be the most frequent allele level mismatch in HLA-C in patients of European ancestry. If this hypothesis is correct, then a negative effect of HLA-C allele level mismatches other than C*03:03/C*03:04 would have been masked.
Methods

Study population
The study included patients reported to the CIBMTR who received a transplant from an 21 to adjust for any bias introduced by the exclusion of nonconsenting survivors. This adjustment is standard for all studies using NMDP data.
HLA typing and HLA mismatches
High-resolution typing for HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 was performed prospectively for some loci and retrospectively for other loci as described previously.
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No distinction between high-resolution/allele level and low-resolution/antigen level was made for disparities in HLA-A, -B, -DRB1 loci. HLA-DPB1 loci were typed in a subset of patients and donors, but the impact of individual or combined mismatches in the HLA-DQB1 and -DPB1 loci on outcome was not evaluated since prior studies in this population have not shown associations with survival. The 7/8 groups were classified into mutually exclusive categories according to the mismatches in HLA-C as follows: 1) C*03:03/C*03:04 allele level HLA mismatches (7/8 C*03:03/C*03:04MM); 2) other HLA-C allele level mismatches (involving allele mismatches with identical first twodigits of the name other than C*03:03/C*03:04 (henceforth 7/8 Callele≠03:03/03:04MM)); 3) C-antigen level mismatches, involving alleles with differences in the first field or two-digit name (7/8 C-antigenMM) and: 4) mismatches in alleles or antigens of HLA-A, -B or -DRB1 (7/8 Other MM). The outcomes in these 7/8
groups were compared to those of patients matching in 8/8 alleles. In addition, the outcomes in the 7/8 group with the HLA mismatch C*03:03/C*03:04 were compared with the outcomes in other 7/8 HLA mismatched individually or combined. The transplants with two mismatches (6/8) were classified into three groups: 1) those in which one of the HLA mismatches was C*03:03/C*03:04 (6/8 C*03:03/C*03:04MM); 2) those in which one of the mismatches occurred in HLA-C and was not C*03:03/C*03:04 (6/8
Other HLA-CMM); and 3) both mismatches occurred in loci other than HLA-C (6/8
Other MM). The outcomes in each of the 6/8 groups were compared with the outcomes in the 7/8 group in which the mismatch did not take place in HLA-C (7/8 Other MM).
Directional mismatches were considered in the analysis of graft-versus-host disease (GVHD) and engraftment, as described. 6 ,7
Definitions of outcomes
The primary outcome was overall survival (OS), defined as time from graft infusion (day 0) to death from any cause. A number of secondary end points were also analyzed.
Neutrophil engraftment was defined as achieving an absolute neutrophil count greater than 500x10 6 cells/L by day 28 that was maintained for 3 consecutive measurements.
aGVHD grade III -IV was defined by the Glucksberg scale. 
Biostatistical methods
Probabilities for OS and DFS were calculated using the Kaplan-Meier estimator. Survival curves were compared using the log-rank test. Neutrophil engraftment was considered a dichotomous outcome and analyzed by logistic regression using a pseudo-value approach. Values for other outcomes were estimated using the cumulative incidence function. 7 The point estimates of the adjusted cumulative incidence rates were based on proportional sub-distribution hazards models. [25] [26] [27] The adjusted cumulative incidences were compared at 100 days after transplantation for acute GVHD III-IV, at 5 years after transplantation for TRM, and at 2 years for chronic GVHD. 
Single locus mismatches
The 7/8 C*03:03/C*03:04MM group was not significantly different from the 8/8 HLA matched transplants in any transplant outcome. Indeed, the hazard ratios for survival, DFS, TRM, grade II-IV, and III-IV aGVHD in the C*03:03/C*03:04 mismatched transplants compared to the 8/8 group suggest that these outcomes were essentially identical all with p-values > 0.73 ( Table 2 ). The 8/8 matched group and the 7/8 C*03:03/C*03:04MM group had virtually identical adjusted overall survival ( Fig. 1a) and DFS (Fig. 1b ) five years after transplantation; similarly, these groups also had comparable incidence of grade III-IV aGVHD ( Fig. 1c ) 100 days after transplantation and TRM ( Fig. 1d ) five years after transplantation. The adjusted probabilities for the 8/8
and 7/8 C*03:03/C*03:04MM groups for OS (39%, CI 37-40% and 41% CI 33-49%, respectively) and DFS (36%, CI 34-37% and 36% CI 29-44%, respectively) 5 years after transplantation were virtually identical; similarly, these groups showed similar incidences of grades III-IV aGVHD 100 days after transplantation (21%, CI 20-22% and 22% CI 15-28%, respectively). The adjusted probabilities for TRM 5 years after transplantation in the 8/8 (36%, CI 35-38%) and 7/8 C*03:03/C*03:04MM (35%, CI 27-43%) also were not significantly different (Supplemental Table 2 ).
In contrast, mismatching at a single antigen of HLA-C (7/8 C-antigenMM) and a single allele or antigen mismatch of HLA-A, -B, or -DRB1 (7/8 Other MM) was associated with lower OS and DFS, as well as with higher TRM and aGVHD III-IV compared to the 8/8
HLA-matched pairs ( Table 2 , Fig. 1 ). The adjusted probabilities for OS 5 years after transplantation in the 7/8 C-antigen MM (29%, CI 26-32%) and the 7/8 Other MM (31%, CI 28-34%) were lower than those observed for the 7/8 C*03:03/C*03:04MM (p = 0.007 and 0.02, NS, respectively, Supplemental Table 2 ) and the 8/8 (p <0.0001 for both comparison, (Supplemental Table 2 )) groups. TRM and aGVHD III-IV were significantly higher in the 7/8 Other MM group compared with the C*03:03/C*03:04MM group (Table 3) . Similarly, the 7/8 C-antigen MM group presented significantly higher incidence of TRM and worse OS than the C*0303/C*0304MM (Table 3 ).
The 7/8 C-allele≠03:03/03:04MM had a small sample size (n=61), which may have limited the power to detect differences. In spite of this limitation, grade II-IV aGVHD was significantly higher in this group (HR=1.56 and p=0.0096) compared with the 8/8 group ( Table 2 ). The 7/8 C-allele≠03:03/03:04MM also had lower OS adjusted probabilities (27%, CI 16-38%) than the 8/8 and 7/8 C*03:03/C*03:04MM groups, although these differences were not statistically significant (Tables 2 and 3 ). The point estimates in the 7/8 C-allele≠03:03/03:04MM and the 7/8 antigen level mismatched groups presented comparable adjusted probabilities for DFS 5 years after transplantation (ranging 25-29%), grade III-IV aGVHD at day 100 (ranging 30-33%), and TRM 5 years after transplantation (ranging 47-51%) (Supplemental Table 2 ).
The mismatch C*03:03/C*03:04 was also scored in the host-versus-graft or graft-versushost vector; there were no significant differences in any of the transplant outcomes for this pairwise comparison or for the individual comparison with the 8/8 matched transplants (data not shown).
There were no significant differences between any of the 7/8 and 8/8 matched pairs for neutrophil engraftment and chronic GVHD. Table 2 also shows that there was no reduction in relapse or an enhanced graft versus leukemia effect conferred by any of the single HLA mismatch groups, an observation made in recent studies. [6] [7] [8] 10 Outcomes in groups with two HLA mismatches
The transplants with two mismatches at HLA-A, B, C, and DRB1 loci were classified into three mutually exclusive groups according to the occurrence of one mismatch in the alleles C*03:03/C*03:04 (n=60), or the presence of one mismatch in HLA-C other than
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From C*03:03/C*03:04 (n=550), or in which none of the mismatches occurred in HLA-C (n=106). The outcomes in each of these groups were compared with those in 7/8 transplants presenting a single antigen or allele mismatch in HLA-A, -B, or -DRB1 loci (n=959). These comparisons were designed to evaluate the effect of a specific second HLA mismatch. Groups differed in the year of transplantation (p<0.0001), graft type utilized (p<0.0001), conditioning regimen (p=0.003), GvHD prophylaxis (<0.0001), patient age (p<0.0001), and diagnosis (p=0.0009).
Transplants matched at 6/8 alleles where at least one mismatch occurred in HLA-C (6/8
Other HLA-CMM) and was not C*03:03/C*03:04 had significantly worse survival (HR = 1.38; p <0.0001), DFS (HR = 1.33; p <0.0001) and TRM (HR = 1.35; p =0.0001) compared to the 7/8 matched group (Supplemental Table 3 ). The transplants with two or more mismatches that included a mismatch at C*03:03/C*03:04 or those including mismatches only in HLA-A, -B, or -DRB1 (no C mismatch) showed no significant differences in any outcome when compared to the 7/8 reference group, although with hazard ratios that suggest risk for adverse outcomes for OS (1.29 and 1.21, respectively), DFS (1.27 and 1.16, respectively) and TRM (1.17 and 1.20, respectively).
Discussion
In spite of the higher prevalence of mismatches at HLA-DQ and -DP loci, we could not 
32
Transplants in which the patient and donor present HLA mismatches in alleles that differ by substitutions at these residues presented increased risk for acute and chronic GVHD and death.
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Among the common single mismatches found in the present and other studies 7,34,35 in 7/8 matched transplants, the mismatch in the alleles C*03:03/C*03:04 is unique in terms of the location of the structural differences; in contrast, virtually all other common mismatches differ by at least one amino acid substitution at residues that affect peptide binding 35 (data not shown from the present study). Therefore, in the evaluation of HLA mismatches, the examination of the location of the distinguishing substitutions being replacements at residues 131 and 103, respectively, that are also located at connecting loops. Therefore, these mismatches could potentially be permissible and could benefit patients of South, Central, or Meso American descent where these HLA-B35 alleles are found associated tightly with the same allele at HLA-C locus (C*04:01). 36 It is conceivable that after allogeneic HSCT, the mismatch in the HLA alleles C*03:03/C*03:04 may elicit allo-reactive T-cell responses through indirect recognition of C*03-derived peptides complexed with MHC-heterodimer molecules in the patient's tissues. In this scenario, the recognition of HLA derived peptides would resemble that of a minor histocompatibility antigen with similar impact in transplant outcomes.
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Although the present study indicates that the single mismatch in the HLA alleles C*03:03/C*03:04 has no effect on outcome, this mismatch could be significant if combined with mismatches in other loci in a similar manner as the effect observed for mismatches in the low expression HLA loci -DRB3/4/5, -DQ and -DP, 41 as well as for the presence of adverse outcome factors 17 that have weak or no effect when evaluated individually.
The results described here confirm that the allele pair C*03:03/C*03:04 is the most frequent allele level mismatch in HLA-C in this Caucasian cohort. Although the differential serologic recognition of Cw9 (serotype of C*03:03) and Cw10 (serotype of C*03:04) by allo-antibodies was identified several decades ago, 42 no studies have been conducted to examine whether humoral responses may be mounted following allo- 39. Katagiri T, Shiobara S, Nakao S, et al. Mismatch of minor histocompatibility antigen contributes to a graft-versus-leukemia effect rather than to acute GVHD, ‡Adjusted for CMV match, conditioning regimen, disease type, disease stage, GVHD prophylaxis, patient age, donor age, sex match, graft type, Karnofsky score and year of transplantation. §Adjusted for conditioning regimen, disease stage, Karnofsky score, patient age, sex match, year of transplantation, disease type, GVHD prophylaxis, in vivoTcell depletion. | |Adjusted for disease type, graft type, sex match, year of transplantation, GVHD prophylaxis, in vivoT-cell depletion, conditioning regimen and patient age. ¶Adjusted for disease stage, donor age, conditioning regimen, graft type, in vivo T-cell depletion, GVHD prophylaxis and Karnofsky score. &Adjusted for time from diagnosis to transplantation, Karnofsky score, patient age, sex match, disease type, disease stage, conditioning regimen and year of transplantation. ##Adjusted for donor age, graft type, vivoT-cell depletion, patient age, sex match, year of transplantation, disease type, GVHD prophylaxis. 
